Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

Sudhir Kumar Yadav; Devika Soin; Kouichi Ito; Suhayl Dhib-Jalbut

doi:10.1007/s00109-019-01761-5

Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

Sudhir Kumar Yadav, Devika Soin, Kouichi Ito, Suhayl Dhib-Jalbut

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

Original language	English (US)
Pages (from-to)	463-472
Number of pages	10
Journal	Journal of Molecular Medicine
Volume	97
Issue number	4
DOIs	https://doi.org/10.1007/s00109-019-01761-5
State	Published - Apr 12 2019

All Science Journal Classification (ASJC) codes

Molecular Medicine
Drug Discovery
Genetics(clinical)

Keywords

Dimethyl fumarate
Immunomodulation
Neuroprotection
Nuclear factor erythroid-derived 2-related factor
Relapsing–remitting multiple sclerosis

Access to Document

10.1007/s00109-019-01761-5

Fingerprint Dive into the research topics of 'Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis'. Together they form a unique fingerprint.

Cite this

@article{1ad52517947e48a6b2ab70968c1dd458,

title = "Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis",

abstract = "Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.",

keywords = "Dimethyl fumarate, Immunomodulation, Neuroprotection, Nuclear factor erythroid-derived 2-related factor, Relapsing–remitting multiple sclerosis",

author = "Yadav, {Sudhir Kumar} and Devika Soin and Kouichi Ito and Suhayl Dhib-Jalbut",

year = "2019",

month = apr,

day = "12",

doi = "10.1007/s00109-019-01761-5",

language = "English (US)",

volume = "97",

pages = "463--472",

journal = "Journal of Molecular Medicine",

issn = "0946-2716",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

AU - Yadav, Sudhir Kumar

AU - Soin, Devika

AU - Ito, Kouichi

AU - Dhib-Jalbut, Suhayl

PY - 2019/4/12

Y1 - 2019/4/12

N2 - Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

AB - Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

KW - Dimethyl fumarate

KW - Immunomodulation

KW - Neuroprotection

KW - Nuclear factor erythroid-derived 2-related factor

KW - Relapsing–remitting multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85062592371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062592371&partnerID=8YFLogxK

U2 - 10.1007/s00109-019-01761-5

DO - 10.1007/s00109-019-01761-5

M3 - Review article

C2 - 30820593

AN - SCOPUS:85062592371

VL - 97

SP - 463

EP - 472

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 4

ER -